808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

• Mariano Severgnini,
• Michael Manos,
• Anita Giobbie-Hurder,
• Osama Rahma,
• F Stephen Hodi,
• Kevin Tyan,
• Joanna Baginska,
• Martha Brainard,
• James Cleary,
• Benjamin Schlechter,
• Anna Maloney,
• Rizwan Romee

Affiliations

Mariano Severgnini

Aff2 0000 0001 2106 9910grid.65499.37Dana-Farber Cancer Institute Boston MA USA

Michael Manos

2Dana-Farber Cancer Institute, Boston, MA, USA

Anita Giobbie-Hurder

2Dana-Farber Cancer Institute, Boston, MA, USA

Osama Rahma

2Dana-Farber Cancer Institute, Boston, MA, USA

F Stephen Hodi

Dana-Farber Cancer Institute, Boston, MA, USA

Kevin Tyan

1Harvard Medical School, Somerville, MA, USA

Joanna Baginska

Dana-Farber Cancer Institute, Boston, MA, USA

Martha Brainard

Dana-Farber Cancer Institute, Boston, MA, USA

James Cleary

Dana-Farber Cancer Institute, Boston, MA, USA

Benjamin Schlechter

Dana-Farber Cancer Institute, Boston, MA, USA

Anna Maloney

Dana-Farber Cancer Institute, Boston, MA, USA

Rizwan Romee

Dana-Farber Cancer Institute, Boston, MA, USA